|
1
|
Terpos E, Ntanasis-Stathopoulos I,
Gavriatopoulou M and Dimopoulos MA: Pathogenesis of bone disease in
multiple myeloma: From bench to bedside. Blood Cancer J. 8:72018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nahi H, Våtsveen TK, Lund J, Heeg BM,
Preiss B, Alici E, Møller MB, Wader KF, Møller HE, Grøseth LA, et
al: Proteasome inhibitors and IMiDs can overcome some high-risk
cytogenetics in multiple myeloma but not gain 1q21. Eur J Haematol.
96:46–54. 2016. View Article : Google Scholar
|
|
3
|
Harding T, Baughn L, Kumar S and Van Ness
B: The future of myeloma precision medicine: Integrating the
compendium of known drug resistance mechanisms with emerging tumor
profiling technologies. Leukemia. 33:863–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Velez R, Turesson I, Landgren O,
Kristinsson SY and Cuzick J: Incidence of multiple myeloma in Great
Britain, Sweden, and Malmö, Sweden: The impact of differences in
case ascertainment on observed incidence trends. BMJ Open.
6:e0095842016. View Article : Google Scholar
|
|
5
|
Chen D, Zhou D, Xu J, Zhou R, Ouyang J and
Chen B: Prognostic value of 1q21 gain in multiple myeloma. Clin
Lymphoma Myeloma Leuk. 19:e159–e164. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Handa H, Murakami Y, Ishihara R,
Kimura-Masuda K and Masuda Y: The role and function of microRNA in
the pathogenesis of multiple myeloma. Cancers (Basel). 11:13782019.
View Article : Google Scholar
|
|
8
|
Adamia S, Abiatari I, Amin SB, Fulciniti
M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC and
Anderson KC: The effects of MicroRNA deregulation on pre-RNA
processing network in multiple myeloma. Leukemia. 34:167–179. 2020.
View Article : Google Scholar
|
|
9
|
Xu YY, Song YQ, Huang ZM, Zhang HB and
Chen M: MicroRNA-26a inhibits multiple myeloma cell growth by
suppressing cyclin-dependent kinase 6 expression. Kaohsiung J Med
Sci. 35:277–283. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tian F, Zhan Y, Zhu W, Li J, Tang M, Chen
X and Jiang J: MicroRNA-497 inhibits multiple myeloma growth and
increases susceptibility to bortezomib by targeting Bcl-2. Int J
Mol Med. 43:1058–1066. 2019.
|
|
11
|
Gupta N, Kumar R, Seth T, Garg B, Sati HC
and Sharma A: Clinical significance of circulatory microRNA-203 in
serum as novel potential diagnostic marker for multiple myeloma. J
Cancer Res Clin Oncol. 145:1601–1611. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang YK, Wang H, Leng Y, Li ZL, Yang YF,
Xiao FJ, Li QF, Chen XQ and Wang LS: Overexpression of microRNA-29b
induces apoptosis of multiple myeloma cells through down regulating
Mcl-1. Biochem Biophys Res Commun. 414:233–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jia CM, Tian YY, Quan LN, Jiang L and Liu
AC: miR-26b-5p suppresses proliferation and promotes apoptosis in
multiple myeloma cells by targeting JAG1. Pathol Res Pract.
214:1388–1394. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Gong X, Tian K, Chen D, Sun J,
Wang G and Guo M: miR-25 promotes glioma cell proliferation by
targeting CDKN1C. Biomed Pharmacother. 71:7–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sanchez-Mejias A, Kwon J, Chew XH, Siemens
A, Sohn HS, Jing G, Zhang B, Yang H and Tay Y: A novel
SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer.
Int J Cancer. 144:311–321. 2019. View Article : Google Scholar
|
|
16
|
Navarro A, Diaz T, Tovar N, Pedrosa F,
Tejero R, Cibeira MT, Magnano L, Rosiñol L, Monzó M, Bladé J and
Fernández de Larrea C: A serum microRNA signature associated with
complete remission and progression after autologous stem-cell
transplantation in patients with multiple myeloma. Oncotarget.
6:1874–1883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiang T, Hu AX, Sun P, Liu G, Liu G and
Xiao Y: Identification of four potential predicting miRNA
biomarkers for multiple myeloma from published datasets. PeerJ.
5:e28312017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised international staging system
for multiple myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
International Myeloma Working Group:
Criteria for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: A report of the
international myeloma working group. Br J Haematol. 121:749–757.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Franke TF: PI3K/Akt: Getting it right
matters. Oncogene. 27:6473–6488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X and Jiang X: PTEN: A default
gate-keeping tumor suppressor with a versatile tail. Cell Res.
18:807–816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Razumilava N, Bronk SF, Smoot RL, Fingas
CD, Werneburg NW, Roberts LR and Mott JL: miR-25 targets
TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and
promotes apoptosis resistance in cholangiocarcinoma. Hepatology.
55:465–475. 2012. View Article : Google Scholar
|
|
25
|
Feng S, Pan W, Jin Y and Zheng J: MiR-25
promotes ovarian cancer proliferation and motility by targeting
LATS2. Tumour Biol. 35:12339–12344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boguslawska J, Rodzik K, Poplawski P,
Kędzierska H, Rybicka B, Sokół E, Tański Z and Piekiełko-Witkowska
A: TGF-beta1 targets a microRNA network that regulates cellular
adhesion and migration in renal cancer. Cancer Lett. 412:155–169.
2018. View Article : Google Scholar
|
|
27
|
Huo J, Zhang Y, Li R, Wang Y, Wu J and
Zhang D: Upregulated MicroRNA-25 mediates the migration of melanoma
cells by targeting DKK3 through the WNT/β-catenin pathway. Int J
Mol Sci. 17:11242016. View Article : Google Scholar
|
|
28
|
Ning L, Zhang M, Zhu Q, Hao F, Shen W and
Chen D: miR-25-3p inhibition impairs tumorigenesis and invasion in
gastric cancer cells in vitro and in vivo. Bioengineered. 11:81–90.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu H, Ma L and Wang J: Overexpression of
miR-25 is associated with progression and poor prognosis of
cholangiocarcinoma. Exp Ther Med. 18:2687–2694. 2019.PubMed/NCBI
|
|
30
|
Chen H, Pan H, Qian Y, Zhou W and Liu X:
MiR-25-3p promotes the proliferation of triple negative breast
cancer by targeting BTG2. Mol Cancer. 17:42018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wan W, Wan W, Long Y, Li Q, Jin X, Wan G,
Zhang F, Lv Y, Zheng G, Li Z and Zhu Y: MiR-25-3p promotes
malignant phenotypes of retinoblastoma by regulating PTEN/Akt
pathway. Biomed Pharmacother. 118:1091112019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peng G, Yang C, Liu Y and Shen C:
miR-25-3p promotes glioma cell proliferation and migration by
targeting FBXW7 and DKK3. Exp Ther Med. 18:769–778. 2019.PubMed/NCBI
|
|
33
|
Kim YK, Yu J, Han TS, Park SY, Namkoong B,
Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK and Kim VN: Functional links
between clustered microRNAs: Suppression of cell-cycle inhibitors
by microRNA clusters in gastric cancer. Nucleic Acids Res.
37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Tan W, Neo TW, Aung MO, Wasser S,
Lim SG and Tan TM: Role of the miR-106b-25 microRNA cluster in
hepatocellular carcinoma. Cancer Sci. 100:1234–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Poliseno L, Salmena L, Riccardi L, Fornari
A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, et
al: Identification of the miR-106b~25 microRNA cluster as a
proto-oncogenic PTEN-targeting intron that cooperates with its host
gene MCM7 in transformation. Sci Signal. 3:ra292010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang Y, Chang H and Chen G: Effects of
microRNA-20a on the proliferation, migration and apoptosis of
multiple myeloma via the PTEN/PI3K/AKT signaling pathway. Oncol
Lett. 15:10001–10007. 2018.PubMed/NCBI
|
|
38
|
Qu L, Gao Y, Sun H, Wang H, Liu X and Sun
D: Role of PTEN-Akt-CREB signaling pathway in nervous system
impairment of rats with chronic arsenite exposure. Biol Trace Elem
Res. 170:366–372. 2016. View Article : Google Scholar
|
|
39
|
Aziz AUR, Farid S, Qin K, Wang H and Liu
B: PIM kinases and their relevance to the PI3K/AKT/mTOR pathway in
the regulation of ovarian cancer. Biomolecules. 8:72018. View Article : Google Scholar :
|
|
40
|
Waniczek D, Śnietura M, Lorenc Z,
Nowakowska-Zajdel E and Muc-Wierzgon M: Assessment of PI3K/AKT/PTEN
signaling pathway activity in colorectal cancer using quantum
dot-conjugated antibodies. Oncol Lett. 15:1236–1240.
2018.PubMed/NCBI
|
|
41
|
Yu T, Li L, Liu W, Ya B, Cheng H and Xin
Q: Silencing of NADPH oxidase 4 attenuates hypoxia resistance in
neuroblastoma cells SH-SY5Y by inhibiting PI3K/Akt-dependent
glycolysis. Oncol Res. 27:525–532. 2019. View Article : Google Scholar
|
|
42
|
Xu H, Li J and Zhou ZG: NEAT1 promotes
cell proliferation in multiple myeloma by activating PI3K/AKT
pathway. Eur Rev Med Pharmacol Sci. 22:6403–6411. 2018.PubMed/NCBI
|
